The use of molecular biomarkers in minimally invasive sampling opens a promising perspective for the early detection of endometrial cancer. This is the conclusion reached by the members of Screenwide research group, formed by researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO-Hospitalet).
You are here
The prevalence of anal high-grade squamous intraepithelial lesions (HSIL), which precede anal cancer, is much higher in women living with HIV than previously reported, a multi-site, national study involving hundreds of patients has found. Conducted by researchers from the AIDS Malignancy Consortium, a National Cancer Institute-supported clinical trials group, the results call for new strategies to be developed for wider screening of women living with HIV, who have disproportionally higher rates of anal cancer compared to the general population of women.
A potential new immune-based therapy to treat precancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial.
The shot, a therapeutic vaccine, injects a specific protein that triggers an immune system response to attack high-risk HPV types that cause nearly all cervical cancer precursors, known as cervical intraepithelial neoplasia, or CIN.
Cervical cancer can be insidious. Changes to the cervix are often detected with a pap smear, but for those with limited access to health care, cervical and vaginal cancers can go unnoticed for years--silently growing, spreading and invading other organs--and by the time they're detected, they may be so advanced that the patient's prognosis is poor and her treatment options few.
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that mailing self-collection kits to test for high-risk human papillomavirus infection has the potential to boost cervical cancer screening - especially for low-income women who are overdue for testing.
A new study has shown that genital warts may promote HIV sexual transmission and, in turn, their treatment and prevention could help decrease the spread of the disease.
The Pap smear test has been used widely for the past five decades to understand and screen for early signs of cervical cancer. The conventional test has been largely replaced by a liquid-based Pap cytology test. Soon it may be replaced by another test – the Human papilloma virus test or the HPV test finds new research.
The University of New Mexico Comprehensive Cancer Center has joined the other 69 cancer centers designated by the National Cancer Institute to issue a statement urging increased vaccination for human papillomavirus.
Nearly 80 million Americans, or one in four people in the United States, are infected with HPV. Of those, more than 31,000 will be diagnosed with an HPV-related cancer this year. The HPV vaccine has been shown to prevent infections, but vaccination rates in the U.S. remain low.
The American Society of Clinical Oncology (ASCO) today issued a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer. This is the first guideline on primary prevention of cervical cancer that is tailored to multiple regions of the world with different levels of socio-economic and structural resource settings, offering evidence-based guidance to health care providers worldwide.
As of this year, kids under the age of 15 only need 2 doses of HPV vaccine. New research out of Boston Medical Center, published online in the STD Journal, is the first published clinical evidence to support new recommendations by the Center for Disease Control and Prevention (CDC) for a two-dose HPV vaccine to prevent genital warts. BMC researchers found that the two-dose human papillomavirus (HPV) vaccine provides the same level of protection against genital warts as three doses, when given as directed.